Solutions › C-Suite / Executive
Regulatory risk is Pipeline risk. Market risk. Revenue risk.
In Life Sciences, the regulatory landscape directly determines what you can bring to market, when you can bring it, and what it costs to keep it there. Most executives rely entirely on filtered briefings from their regulatory team to understand that landscape — and the filtering introduces lag, gaps, and dependency. Lexim Sphere gives executive leadership the direct, business-level visibility into regulatory risk that most have never had.
The Business Dimension
Every regulatory decision has a
business consequence.
Regulatory affairs isn't a compliance function that sits separate from the business. It's the function that determines whether your pipeline reaches market, when it does, and what it costs when it doesn't. These are the three dimensions of regulatory risk that belong in executive conversations.
Pipeline Risk
The path to approval depends on regulatory alignment you may not have.
A submission that doesn't reflect current regulatory requirements doesn't get approved — it gets a Complete Response Letter, a clinical hold, or a deficiency notice. Every gap between your documentation and current requirements is a potential delay measured in months or quarters.
-
FDA Complete Response Letter adds 6–18 months to NDA approval
-
510(k) hold for insufficient clinical data delays market entry
-
EU MDR technical file deficiency delays CE marking
Market Access Risk
Post-approval compliance failures threaten the revenue you're counting on.​​
Approval isn't the end of the regulatory relationship — it's the beginning of an ongoing compliance obligation. Manufacturing changes, labeling updates, post-market surveillance requirements, and evolving standards all create post-approval risk that, when unmanaged, becomes enforcement action, recall, or market withdrawal.
-
Warning letter triggers manufacturing shutdown and revenue loss
-
Recall of approved product — reputational and financial impact
-
Labeling non-compliance blocks market access in key territories
Competitive Risk
Your competitors' regulatory activity directly affects your market position.
Regulatory strategy is competitive strategy. A competitor who files earlier, clears faster, or identifies a more efficient approval pathway gains market position. A competitor's recall or enforcement action creates opportunity. Most executives have no visibility into this competitive regulatory landscape until it's already changed the market.
-
Competitor clears predicate device — your 510(k) strategy needs updating
-
Competitor recall in your category creates window for market share
-
Competitor fast-track designation signals your pathway risk
What Changes
Before and after
Lexim Sphere.
These are the specific executive-level situations that Sphere changes — in how fast you can respond, how confidently you can brief the board, and how clearly you see the risk.
BEFORE
A major FDA guidance relevant to your lead product publishes on Monday. You find out Friday, after your VP Regulatory has had time to read it, assess it, and prepare a briefing — by which point some internal decisions may have already been made without that context.
AFTER
Synthesis surfaces the guidance Monday morning with an executive summary and organizational impact already mapped. You know what it means for your pipeline — and for which functions — the same day it publishes, not five days later.
BEFORE
The Board asks about regulatory risk in your Q3 pipeline review. You present what your VP Regulatory prepared — a briefing based on the regulatory landscape as it was two weeks ago. You don't know what you don't know.
AFTER
Your pipeline regulatory risk picture is continuously current. The Board presentation reflects the landscape as it is today — every relevant update, every competitive development, every compliance status — not as it was when your team last had time to brief you.
BEFORE
Business development asks whether you can enter a new market. Your regulatory team needs two to three weeks to build a credible regulatory landscape assessment. The business development decision stalls waiting for regulatory input.
AFTER
Global pulse builds the regulatory picture for any market — requirements, pathways, timelines, recent activity — in hours. Business development gets regulatory input at the speed of the business decision, not the speed of manual research.
BEFORE
A competitor gets an FDA warning letter in your product category. You hear about it from your sales team three weeks later, after it's already been discussed in industry circles and your customers have started asking questions.
AFTER
Periscope monitors your competitive landscape continuously and surfaces the warning letter the day it publishes — with the competitive context already assembled. You're informed before your customers are, and positioned to respond strategically.
Designed for Executives
You don't need to understand the regulatory landscape. You need to understand what it means for your business.
Sphere is designed to surface the business-level signal, not the regulatory detail. These are the questions executives actually ask — and how Sphere answers them without requiring you to become a regulatory expert.
"Is our Q3 submission still on track given recent FDA activity?"
​
Synthesis and Bridge give your team a continuously current picture of your submission's alignment with current requirements. The answer is always available — not dependent on when someone last checked.
Synthesis · Bridge · Vigil
"What are our biggest regulatory risks heading into next year?"
​
Synthesis Six Impact Analysis maps regulatory developments to organizational risk by function. Your VP Regulatory can give you a current, comprehensive risk picture in a form ready for board presentation.
Synthesis Six · Global pulse · FDA Pulse
"What's the regulatory picture if we enter the Japanese market?"
​
Global pulse builds the PMDA regulatory landscape on demand — requirements, approval pathways, timelines, and recent activity — giving your team a credible market entry assessment in hours rather than weeks.
Global pulse · Synthesis · Relay
"What's happening with our main competitor regulatorily?"
​​
Periscope monitors your competitive landscape continuously — filings, clearances, enforcement actions, clinical activity — and surfaces every development as it occurs. Competitive regulatory intelligence, always current.
Periscope · Device Lens · Global pulse
"Are we audit-ready if FDA shows up next month?"
​
Vigil and Bridge give your QA team continuous compliance maintenance — tracking every relevant quality standard update and running gap assessments against your SOPs automatically. Audit readiness isn't a sprint; it's a state.
Bridge · Vigil · Cabinet
"How do we get to European approval faster?"
​​
Clarity compares your documentation across jurisdictions to identify exactly what needs to change for EU submission. Relay handles translation. Synthesis tracks the EU regulatory landscape. Your European pathway is visible and actionable.
Clarity · Relay · Synthesis
In Your Industry
Executive scenarios in MedTech and Pharma.
MEDICAL DEVICE
MedTech CEO / C-Suite
SCENARIO
You're considering acquiring a company with an active 510(k) pipeline and two cleared devices in your target category. Your M&A team needs a regulatory due diligence picture — competitive landscape, clearance history, enforcement activity, and regulatory risk — in 72 hours before the LOI decision.
WITH SPHERE
Device Lens gives you the target company's complete FDA submission and clearance history. Periscope surfaces their enforcement and safety record. Synthesis maps the regulatory landscape in their product category. You have a regulatory due diligence picture in 72 hours — not 72 days.
PHARMA
Pharma CEO / C-Suite
SCENARIO
Your lead asset is in Phase 3. Three ICH guidelines relevant to your submission strategy have been updated in the last year. Your Board wants to know if your NDA timeline is still credible and what the regulatory risk exposure is. The question lands in the board meeting — not two weeks before it.
WITH SPHERE
Docket has tracked every ICH guideline update with full lifecycle history. Bridge has assessed their impact on your CMC documentation. Your VP Regulatory can answer the Board's question with a current, defensible risk picture — not an estimate based on the last time someone checked.
Executive-Level Demo
See your regulatory risk picture
as it actually is today.
Book an executive-level session — 30 minutes, focused on your industry, your pipeline, and your competitive landscape. We'll show you what Sphere sees in your regulatory world right now — and what that means for the business decisions you're making this quarter.